In the SURMOUNT-1 trial, tirzepatide produced dose-dependent weight reductions, with average losses approaching or exceeding ~20% at higher doses in adults with obesity who did not have diabetes, numbers that markedly exceed historical pharmacotherapy benchmarks
Watada H, Kaneko S, Komatsu M, Agner BR, Nishida T, Ranthe M, Nakamura J
PMID: 27 FinotelloFMayerCPlattnerCLaschoberGRiederDHacklHet al
It is responsive nutrition that acknowledges hormonal reality
Mechanism-of-action-mediated DDIs are currently limited to those involving delayed gastric emptying, and most studies have found them to be clinically insignificant
Visualize Your Semaglutide Clearance Use the free GLP3Planner calculator to model how semaglutide levels decay after your last dose, then map your tirzepatide titration schedule from 2.5mg to your target dose